Martin Dow Pharmaceuticals, a contract manufacturing organization (CMO) based in Meymac, France, serves the pharmaceutical sector throughout Europe and beyond.
We are continuously innovating and developing high-performing pharmaceutical solutions at our EU cGMP-compliant facility, that are trusted by consumers and health professionals.
We are dedicated to the highest quality standards, as reflected by our certifications, and are continuously expanding our technological capabilities to deliver on our promise of excellence.
Ali Akhai became the Chairman, Martin Dow Group in October 2018. As an initiative-driven leader, he believes in the significance of diverse business, technological innovation, and talent, ready to lead impact with a desire to enhance the wellbeing of the human race. He is recognized as the face of the Martin Dow Group and has received praise for his in-depth knowledge of numerous facets of the pharmaceutical industry.
After completing his Bachelor of Science business graduate degree (BSc) from Brunel University in the UK, he proceeded to further his education with a double Master's degree. He holds a Master of Science in Global Business from the University of Hertfordshire in the United Kingdom and a Master of Science in International Business Development & Consulting from Novancia Business School in France.
Ali joined the Martin Dow Group of Companies in 2016, and after completing a structured orientation program in Marketing, Finance, Business Development, Human Resources, and Regulatory Affairs, he assumed the role of Business Development Lead, launching eight new items for the Group by mid-2018.
He is playing an essential role in shaping the future of the Martin Dow Group, carrying on his father's vision by guiding the Group's foray into further diversification through successful strategic acquisitions and flexible technologies. As Chairman of the Group, he is leading the 6th Largest Pharmaceutical Group in Pakistan with 2 Healthcare Companies in Europe, into expansion with worldwide partnerships, talent development, and industry influence, to ethically grow through innovation and courage.
He is a visionary and philanthropist, deeply focused on improving the standards of Healthcare, Education and Environment in Pakistan. He represents Pakistan in global events such as World Economic Forum, closely working with global and local key stakeholders to present the Nation’s interest and enhance Pakistan’s international reputation.
Javed is a Group Managing Director and Chief Executive Officer of Martin Dow Group, and under his leadership, the group has experienced unprecedented growth, including the acquisition of the Roche brands and manufacturing facility, leading the Group's growth further through his noteworthy insights.
He is a qualified fellow member of the Institute of Cost & Management Accountants of Pakistan, with over 25 years of experience leading in diversified functions such as Finance, Marketing, International Business, Business Development, Supply Chain, Regulatory Affairs, New Product Development, and Technical Functions.
He has held key positions at a number of leading multinational and national companies, including Abbott Laboratories, Getz Pharma, Briogene, and AJ Research & Pharma (a Saudi Arabian subsidiary of the Al Jomiah Group), the latter two of which he served as the Chief Executive Officer (CEO).
To his credit, he has grown AJ Pharma from a start-up to a global company with a strong presence in both prescription and consumer health markets across seven ASEAN and GCC countries. Under his guidance, the Martin Dow Group continues to grow and set new standards of distinction across the healthcare and pharmaceutical industry in Pakistan and abroad.
David joined Martin Dow Pharmaceuticals in Meymac in October 2019 with years of experience and rich expertise in IT technologies such as SAP, Sage X3, and HFM.
He is a highly professional, detail-oriented, and valued member of the company contributing significantly to performance management, continuous improvement, and quality of the French manufacturing facility.
He has held key roles in finance and supply chain divisions in numerous worldwide pharmaceutical firms, working on vaccines with GSK, food specialties with DSM, and chemicals with the Tessenderlo Group.
He holds a Skema BS in Audit and Control and is APICS certified.
Perrine joined Martin Dow Pharmaceuticals in August 2019, bringing a strong passion to break new ground and push the boundaries of success for the business.
Her pharmaceutical career began in 2007 at AJC Pharma Laboratory, where she rose through the ranks and held leading positions as the Quality Control Manager, Head of Pharmaceutical Affairs, Industrial Manager, and Chief Pharmacist/Qualified Person.
Martin Dow Pharmaceuticals is geared to lead as a quality-driven pharmaceutical, offering world-class medicines trusted by partners, health professionals, and customers alike while making its mark in the pharmaceutical sector under her leadership.
Martin Dow Pharmaceuticals is committed to making available the means necessary to achieve its objectives as part of the development and manufacturing of pharmaceutical products.
We accomplish our key quality objectives through teamwork, dedication, ownership, and support from our talent. Our commitment is to never compromise the safety, compliance, or quality of our products and services.
Quality is based on trust, and we are able to affect this trust through our involvement in the quality of our goods, our enthusiasm, and our leadership.
Martin Dow Pharmaceuticals has become the market leader in several therapeutic areas in the French contract manufacturing business over a short span of time. Our clientele is primarily from Europe, particularly those based in France.
